The TIMP2-418G/C SNP has been previously reported to be associated with risk modulation in colorectal cancer [14] and other cancers including breast cancer [25], gastric cancer [26]; oral cancer [27], prostate cancer [28], ovarian cancer [29], head and neck cancer [23], and non-Hodgkin’s lymphoma [30]. This evidence concerns the gene TIMP2 and colorectal cancer.